OBJECTIVES:   A review of the entire currently listed drugs that had been eligible for subsidy was carried out by the Health Insurance Review and Assessment Service (HIRA) in South Korea. As a result of this review, the government can decide whether a drug should no longer be on the reimbursement drugs list. This study described how these reviews were carried out and the currently listed drugs were changed. METHODS: The currently listed drugs were divided into a total 49 therapeutic groups. The cost-effectiveness analyses were conducted to review of the first therapeutic groups (pilot review, migraine and hyperlipidemia drugs). However, in the others therapeutic groups their clinical usefulness and price reasonableness were reviewed respectively without the cost-effectiveness analysis, because the review framework was changed to improve the efficiency of review by the government. Accordingly, the drugs were delisted when the evidence of clinical usefulness were not founded and drugs' prices were the higher than 80 percentile of the highest price among drugs containing the same ingredients. RESULTS:   As the result of pilot review, 371 drugs (98.1%) were decided to be on the reimbursement drugs list and 7 drugs (1.9%) were delisted. For drugs maintained on the  list, 128 drugs (34.5%) had price cut. After the review framework is changed, 557 drugs (4.1%) were delisted and 3,705 drugs (28.7%) had price cut. For drugs delisted, 446 drugs (80.1%) had no clinical usefulness and 111 drugs (19.9%) were delisted because of several reasons such as fact that pharmaceutical companies did not accept to reduce drug prices. As a result, Of the total 13,844 drugs, 564 drugs (4.1%) were delisted and for drugs remained on the list, 3,831 drugs (28.8%) had price cut. CONCLUSIONS:    This study could be helpful for understanding the currently listed drugs review. In the future, monitoring for the currently listed drugs utilization pattern should be needed.